Skip to content Skip to footer
Subscribe Now
NEWS

Unnatural Products Signs ~$1.8B Licensing Deal with Novartis to Develop Macrocyclic Peptide Therapeutics

Shots: Unnatural Products has entered a research collaboration & licensing agreement with Novartis for an undisclosed cardiovascular program developed using UNP’s AI-enhanced macrocycle platform Under the deal, Novartis will handle IND-enabling studies & subsequent clinical development, manufacturing, & global commercialization of products emerging from the collaboration As per the terms, UNP will receive ~$100M in…
February 19, 2026

Read more

NEWS

Insilico Medicine and CMS Enter Multiple Collaborations to Advance Therapeutics in CNS and Autoimmune Indications

Shots: Insilico Medicine has entered into multiple AI-powered drug discovery collaborations with CMS, focusing on advancing therapeutic programs across CNS & autoimmune disease indications As per the deal, Insilico will leverage its Pharma.AI platform for target discovery & small-molecule design & optimization, while CMS will lead clinical development, regulatory strategy, trials, & commercialization Under the…
February 11, 2026

Read more

NEWS

Iambic Therapeutics Partners with Takeda to Advance AI-Driven Drug Discovery in Oncology and GI/Inflammation

Shots: Iambic has partnered with Takeda in a multi-year tech & discovery collaboration to utilize Iambic’s AI drug discovery models toward advancing select high-priority small molecule programs in Takeda’s Oncology, & GI & Inflammation therapeutic areas The collaboration will leverage Iambic’s AI drug discovery suite & wet lab capabilities, with Takeda also gaining access to…
February 10, 2026

Read more

NEWS

Innovent and Eli Lilly Strike ~$8.85B ex-China Collaboration to Accelerate Oncology & Immunology Programs

Shots: Innovent & Eli Lilly have entered into a strategic collaboration to advance novel medicines in oncology & immunology As per the deal, Innovent will advance the programs from discovery through P-II PoC trial in China using its antibody platforms, while Lilly will receive exclusive rights to develop & commercialize the assets globally, excl. Greater…
February 9, 2026

Read more

NEWS

Saya Biologics and Kashiv BioSciences Partner to Introduce a Biosimilar Supportive Oncology Therapy in Mexico and the CAC Region 

Shots:  Saya Biologics has signed a strategic partnership with Kashiv BioSciences to register and commercialize a supportive oncology therapy in Mexico and the CAC region  As per the deal, the agreement spans 11 countries across Mexico and the CAC region. Saya Biologics will handle regulatory registration, commercialization, and distribution, while Kashiv BioSciences will oversee manufacturing and supply.   Saya has already submitted the regulatory dossier in Mexico,…
February 4, 2026

Read more

NEWS

Origami Therapeutics Collaborates with Ipsen to Develop Protein Degrader Program for Neurodegenerative Disorder

Shots: Origami Therapeutics has entered into a global collaboration & option agreement with Ipsen to develop a small-molecule protein degrader, using Origami’s Oricision platform, for a rare inherited neurodegenerative disorder Under the deal, Ipsen will secure an exclusive option to license the program globally after drug candidate nomination &, upon exercise, would take over worldwide…
February 2, 2026

Read more

NEWS

CSPC Pharmaceutical and AstraZeneca Seal ~$18.5B Long-Acting Peptide Deal for Obesity

Shots: CSPC has entered a strategic collaboration & license deal with AZ to develop long-acting peptides, using CSPC’s sustained-release delivery tech platform & AI-driven peptide drug discovery platform As per the deal, the Group will collaborate with AZ on novel peptide discovery & long-acting delivery, while AZ will gain exclusive global rights (excl. Greater China)…
January 30, 2026

Read more

NEWS

Recordati and Moderna Collaborate To Develop And Commercialize mRNA 3927 in a ~$160M Deal

Shots: Recordati has entered into a collaboration & license deal with Moderna to develop & commercialize mRNA-3927 globally for the treatment of propionic acidemia As per the deal, Moderna will continue to co-develop mRNA-3927 with Recordati, while Recordati will lead global commercialization if approved. In exchange, Moderna will receive $50M upfront, ~$110M in development &…
January 30, 2026

Read more

NEWS

Repertoire Immune Medicines and Eli Lilly Enter ~$1.9B Deal to Develop Tolerizing Therapies for Autoimmune Diseases

Shots: Repertoire has entered into a strategic collaboration with Eli Lilly to develop tolerizing therapies for multiple autoimmune diseases Repertoire will use its DECODE TCR–epitope discovery platform to identify candidates & lead collaboration activities through nomination, after which Lilly will oversee clinical development, manufacturing, regulatory activities, & commercialization Under the terms, Repertoire will receive $85M…
January 29, 2026

Read more

Load more